Scroll

chlorphenamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	616	132-22-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: chlorphenamine chloropheniramine chlorophenylpyridamine chloroprophenpyridamine chlorpheniramine chlorprophenpyridamine chlorpheniramine maleate chlorpheniramine tannate chlorpheniramine polistirex	A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE. Molecular weight: 274.79 Formula: C16H19ClN2 CLOGP: 3.15 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 16.13 ALOGS: -3.72 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

chlorphenamine
chloropheniramine
chlorophenylpyridamine
chloroprophenpyridamine
chlorpheniramine
chlorprophenpyridamine
chlorpheniramine maleate
chlorpheniramine tannate
chlorpheniramine polistirex

A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.

Molecular weight: 274.79
Formula: C16H19ClN2
CLOGP: 3.15
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 16.13
ALOGS: -3.72
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
12	mg	O
12	mg	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	41 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	3.30 L/kg	Lombardo F, Berellini G, Obach RS
S (Water solubility)	3 mg/mL	Bocci G, Oprea TI, Benet LZ
t_half (Half-life)	22 hours	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.70 %	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.48 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Aug. 15, 1950	FDA	BAYER HEALTHCARE LLC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Contraindicated product administered	199.11	10.47	7	67141	217641	63204233
Drug ineffective	194.85	10.47	521	66627	1044244	62377630
Drug intolerance	163.66	10.47	61	67087	308600	63113274
Synovitis	161.15	10.47	9	67139	186909	63234965
Glossodynia	138.96	10.47	14	67134	178862	63243012
Systemic lupus erythematosus	133.34	10.47	29	67119	208889	63212985
Treatment failure	124.28	10.47	29	67119	199014	63222860
Pericarditis	121.10	10.47	4	67144	131575	63290299
Chest discomfort	112.47	10.47	312	66836	109657	63312217
Sinusitis	111.52	10.47	505	66643	226148	63195726

Showing 1 to 10 of 228 entries

Previous1 2 3 4 5…23Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sinusitis	71.39	11.19	136	33350	41266	34882179
Lower respiratory tract infection	67.45	11.19	114	33372	31523	34891922
Delusion of grandeur	66.72	11.19	29	33457	1131	34922314
Rhinalgia	59.50	11.19	26	33460	1027	34922418
Drug ineffective	56.46	11.19	236	33250	456515	34466930
Upper respiratory tract infection	47.88	11.19	101	33385	32958	34890487
Asthma	41.87	11.19	112	33374	42544	34880901
Painful respiration	40.58	11.19	21	33465	1215	34922230
Infusion related reaction	40.22	11.19	127	33359	52930	34870515
Affective disorder	39.40	11.19	33	33453	4327	34919118

Showing 1 to 10 of 98 entries

Previous1 2 3 4 5…10Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	185.65	9.87	534	81122	1080379	78582353
Contraindicated product administered	135.71	9.87	6	81650	157532	79505200
Dyspnoea	121.10	9.87	1374	80282	855651	78807081
Synovitis	119.90	9.87	9	81647	150725	79512007
Chest discomfort	108.05	9.87	349	81307	137695	79525037
Neuropathy peripheral	102.35	9.87	348	81308	140957	79521775
Drug intolerance	95.69	9.87	78	81578	264041	79398691
Treatment failure	95.46	9.87	28	81628	170458	79492274
Cough	91.02	9.87	665	80991	366124	79296608
General physical health deterioration	89.33	9.87	90	81566	275148	79387584

Showing 1 to 10 of 268 entries

Previous1 2 3 4 5…27Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	R06AB04	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted alkylamines
ATC	R06AB54	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Substituted alkylamines
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:37955	H1 receptor antagonists
CHEBI has role	CHEBI:37956	antihistamines
CHEBI has role	CHEBI:50857	anti-allergic drugs
CHEBI has role	CHEBI:50949	SSRI
CHEBI has role	CHEBI:59683	antipruritic drugs
FDA EPC	N0000175587	Histamine-1 Receptor Antagonist
FDA MoA	N0000000190	Histamine H1 Receptor Antagonists

Showing 1 to 10 of 17 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Dermatographic urticaria	indication	7632005	DOID:743
Vasomotor rhinitis	indication	8229003	DOID:4730
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Sneezing	indication	76067001
Common cold	indication	82272006	DOID:10459
Urticaria	indication	126485001
Influenza-like symptoms	indication	315642008
Seasonal allergic rhinitis	indication	367498001

Showing 1 to 10 of 155 entries

Previous1 2 3 4 5…16Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.47	Basic
pKa2	4.14	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
8MG;54.3MG	TUXARIN ER	MAINPOINTE	N206323	June 22, 2015	RX	TABLET, EXTENDED RELEASE	ORAL	9066942	Jan. 3, 2032	TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS

Showing 1 to 1 of 1 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	8.15	WOMBAT-PK	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Kd	7.82	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.17	PDSP
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		Ki	6.67	WOMBAT-PK
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	4.97	WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	5	CHEMBL
Lethal(3)malignant brain tumor-like protein 1	Unclassified	Q9Y468	LMBL1_HUMAN		IC50	4.39	CHEMBL
Lethal(3)malignant brain tumor-like protein 3	Unclassified	Q96JM7	LMBL3_HUMAN		IC50	4.38	CHEMBL
MBT domain-containing protein 1	Unclassified	Q05BQ5	MBTD1_HUMAN		IC50	4.47	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Kd	5.84	SCIENTIFIC LITERATURE

Showing 1 to 10 of 15 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
003391	NDDF
003392	NDDF
004430	NDDF
004431	NDDF
104	INN_ID
113-92-8	SECONDARY_CAS_RN
1405-56-7	SECONDARY_CAS_RN
142429	RXNORM
2725	PUBCHEM_CID
32347	MMSL

Showing 1 to 10 of 38 entries

Previous1 2 3 4Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Alka-Seltzer Plus Cold Sparkling Original PowerFast Fizz	HUMAN OTC DRUG LABEL	3	0280-0060	TABLET, EFFERVESCENT	2 mg	ORAL	OTC monograph final	15 sections
Alka-Seltzer Plus Cold Sparkling Original PowerFast Fizz	HUMAN OTC DRUG LABEL	3	0280-0060	TABLET, EFFERVESCENT	2 mg	ORAL	OTC monograph final	15 sections
Alka-Seltzer Plus Maximum Strength Sinus Congestion and Pain PowerFast Fizz	HUMAN OTC DRUG LABEL	4	0280-0055	TABLET, EFFERVESCENT	2 mg	ORAL	OTC monograph final	15 sections
Alka-Seltzer Plus Maximum Strength Sinus Congestion and Pain PowerFast Fizz	HUMAN OTC DRUG LABEL	4	0280-0055	TABLET, EFFERVESCENT	2 mg	ORAL	OTC monograph final	15 sections
Alka-Seltzer Plus Maximum Strength Sinus Congestion and Pain PowerFast Fizz	HUMAN OTC DRUG LABEL	4	0280-0055	TABLET, EFFERVESCENT	2 mg	ORAL	OTC monograph final	15 sections
Alka-Seltzer Plus Severe Cold and Cough PowerFast Fizz	HUMAN OTC DRUG LABEL	4	0280-0023	TABLET, EFFERVESCENT	2 mg	ORAL	OTC monograph final	16 sections
Alka-Seltzer Plus Severe Cold and Cough PowerFast Fizz	HUMAN OTC DRUG LABEL	4	0280-0023	TABLET, EFFERVESCENT	2 mg	ORAL	OTC monograph final	16 sections
Alka-Seltzer Plus Severe Cold and Cough PowerFast Fizz	HUMAN OTC DRUG LABEL	4	0280-0023	TABLET, EFFERVESCENT	2 mg	ORAL	OTC monograph final	16 sections
Alka-Seltzer Plus Severe Cold and Flu PowerFast Fizz	HUMAN OTC DRUG LABEL	4	0280-0022	TABLET, EFFERVESCENT	2 mg	ORAL	OTC monograph final	16 sections
Alka-Seltzer Plus Severe Cold and Flu PowerFast Fizz	HUMAN OTC DRUG LABEL	4	0280-0022	TABLET, EFFERVESCENT	2 mg	ORAL	OTC monograph final	16 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next